Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study

We report herein the effects of extended-release buprenorphine (BUP-XR), the first FDA-approved subcutaneously injected, monthly treatment for OUD, on patient-centered outcomes.

Source: Journal of Substance Abuse Treatment - November 14, 2019 Category: Addiction Authors: Walter Ling, Vijay R. Nadipelli, Caitlyn T. Solem, Naoko A. Ronquest, Yu-Chen Yeh, Susan M. Learned, Vishaal Mehra, Christian Heidbreder Source Type: research